Amplatzer Piccolo 闭塞器在先天性和后天性心脏病患儿中的标示外使用。

IF 1.6 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Future cardiology Pub Date : 2024-01-01 Epub Date: 2024-09-05 DOI:10.1080/14796678.2024.2355057

Ashley Molloy, Neil Tailor, Ronak Naik, Nithya Swaminathan, Mohammed Absi, Anthony Merlocco, Jason Johnson, Shyam Sathanandam

{"title":"Amplatzer Piccolo 闭塞器在先天性和后天性心脏病患儿中的标示外使用。","authors":"Ashley Molloy, Neil Tailor, Ronak Naik, Nithya Swaminathan, Mohammed Absi, Anthony Merlocco, Jason Johnson, Shyam Sathanandam","doi":"10.1080/14796678.2024.2355057","DOIUrl":null,"url":null,"abstract":"Aim: The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.Methods: Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.Results: The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.Conclusion: The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"459-470"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486072/pdf/","citationCount":"0","resultStr":"{\"title\":\"Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases.\",\"authors\":\"Ashley Molloy, Neil Tailor, Ronak Naik, Nithya Swaminathan, Mohammed Absi, Anthony Merlocco, Jason Johnson, Shyam Sathanandam\",\"doi\":\"10.1080/14796678.2024.2355057\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.Methods: Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.Results: The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.Conclusion: The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.\",\"PeriodicalId\":12589,\"journal\":{\"name\":\"Future cardiology\",\"volume\":\" \",\"pages\":\"459-470\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486072/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/14796678.2024.2355057\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/9/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14796678.2024.2355057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

目的：Amplatzer Piccolo 闭塞器（APO）被批准用于体重大于 700 克婴儿的动脉导管未闭（PDA）闭塞，但也可用于治疗其他病变：方法：对 2022 年 1 月至 2023 年 6 月间使用 APO 治疗 PDA 以外缺陷的儿童进行回顾性审查：9例患者使用了APO，其中3例用于室间隔缺损，4例用于冠状动脉瘘，1例用于心室假性动脉瘤，1例APO部署在先前放置的Amplatzer室间隔封堵器的瘘口内。所有九名患者均成功闭塞，无并发症：APO 是一种多功能装置，除了目前获准用于治疗 PDA 外，还可用于治疗儿童的各种小直径病变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Off-label uses of the Amplatzer Piccolo Occluder in children with congenital and acquired heart diseases.

Aim: The Amplatzer Piccolo Occluder (APO) is approved for patent ductus arteriosus (PDA) occlusion in infants weighing >700 g but could offer versatility to treat other lesions.Methods: Retrospective review of children in whom APO was utilized for defects other than PDA between January 2022 and June 2023.Results: The APO was used in nine patients; three for ventricular septal defects, four with coronary fistulas, one for a ventricular pseudoaneurysm and one where APO deployed within a fenestration of a previously placed Amplatzer Septal Occluder. All nine patients had successful occlusions without complications.Conclusion: The APO is a versatile device that can be used to treat various small diameter lesions in children besides the PDA for which it is currently approved for.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.80

自引率

5.90%

发文量

期刊介绍： Research advances have contributed to improved outcomes across all specialties, but the rate of advancement in cardiology has been exceptional. Concurrently, the population of patients with cardiac conditions continues to grow and greater public awareness has increased patients" expectations of new drugs and devices. Future Cardiology (ISSN 1479-6678) reflects this new era of cardiology and highlights the new molecular approach to advancing cardiovascular therapy. Coverage will also reflect the major technological advances in bioengineering in cardiology in terms of advanced and robust devices, miniaturization, imaging, system modeling and information management issues.